Zobrazeno 1 - 10
of 329
pro vyhledávání: '"Saad Z. Usmani"'
Autor:
María-Victoria Mateos, Ajai Chari, Saad Z. Usmani, Hartmut Goldschmidt, Katja Weisel, Keqin Qi, Anil Londhe, Sandhya Nair, Xiwu Lin, Lixia Pei, Eric Ammann, Rachel Kobos, Jennifer Smit, Trilok Parekh, Alexander Marshall, Mary Slavcev, Philippe Moreau
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 23:385-393
Autor:
Michael A. Thompson, Mario Boccadoro, Xavier Leleu, Jorge Vela-Ojeda, Frits van Rhee, Katja C. Weisel, Robert M. Rifkin, Saad Z. Usmani, Roman Hájek, Gordon Cook, Rafat Abonour, Mira Armour, Kathryn E. Morgan, Su-Peng Yeh, Caitlin L. Costello, Jesus G. Berdeja, Faith E. Davies, Jeffrey A. Zonder, Hans C. Lee, Jim Omel, Andrew Spencer, Evangelos Terpos, Vania T.M. Hungria, Noemi Puig, Chengcheng Fu, Renda H. Ferrari, Kaili Ren, Dawn Marie Stull, Ajai Chari
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 23:e171-e181
Autor:
Oliver Van Oekelen, Karthik Nath, Tarek H. Mouhieddine, Tasmin Farzana, Adolfo Aleman, David T. Melnekoff, Yogita Ghodke-Puranik, Gunjan L. Shah, Alexander Lesokhin, Sergio Giralt, Santiago Thibaud, Adriana Rossi, Cesar Rodriguez, Larysa Sanchez, Joshua Richter, Shambavi Richard, Hearn J. Cho, Ajai Chari, Saad Z. Usmani, Sundar Jagannath, Urvi A. Shah, Sham Mailankody, Samir Parekh
Publikováno v:
Blood. 141:756-765
B-cell maturation antigen (BCMA)–directed chimeric antigen receptor T-cell (CAR T) therapy has demonstrated remarkable efficacy in patients with relapsed/refractory multiple myeloma, and now there are two US Food and Drug Administration–approved
Autor:
Thomas, Martin, Yi, Lin, Mounzer, Agha, Adam D, Cohen, Myo, Htut, A Keith, Stewart, Parameswaran, Hari, Jesus G, Berdeja, Saad Z, Usmani, Tzu-Min, Yeh, Yunsi, Olyslager, Jenna D, Goldberg, Jordan M, Schecter, Deepu, Madduri, Carolyn C, Jackson, William, Deraedt, Katharine S, Gries, John M, Fastenau, Jeremiah J, Trudeau, Muhammad, Akram, Lida, Pacaud, Andrzej, Jakubowiak, Sundar, Jagannath
Publikováno v:
The Lancet Haematology. 9:e897-e905
CARTITUDE-1 is a phase 1b-2 study evaluating ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor T cell therapy with two B-cell maturation antigen-targeting single-domain antibodies, in patients with relapsed or refractory multiple mye
Autor:
Urvi A. Shah, Kylee H. Maclachlan, Andriy Derkach, Meghan Salcedo, Kelly Barnett, Julia Caple, Jenna Blaslov, Linh Tran, Amanda Ciardiello, Miranda Burge, Tala Shekarkhand, Peter Adintori, Justin Cross, Matthew J. Pianko, Kinga Hosszu, Devin McAvoy, Sham Mailankody, Neha Korde, Malin Hultcrantz, Hani Hassoun, Carlyn R. Tan, Sydney X. Lu, Dhwani Patel, Benjamin Diamond, Gunjan Shah, Michael Scordo, Oscar Lahoud, David J. Chung, Heather Landau, Saad Z. Usmani, Sergio Giralt, Ying Taur, C. Ola Landgren, Gladys Block, Torin Block, Jonathan U. Peled, Marcel R.M. van den Brink, Alexander M. Lesokhin
Publikováno v:
Clin Cancer Res
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 28, iss 23
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 28, iss 23
Purpose: Sustained minimal residual disease (MRD) negativity is associated with long-term survival in multiple myeloma. The gut microbiome is affected by diet, and in turn can modulate host immunity, for example through production of short-chain fatt
Autor:
Katja Weisel, Amrita Krishnan, Jordan M. Schecter, Martin Vogel, Carolyn C. Jackson, William Deraedt, Tzu-min Yeh, Arnob Banerjee, Fevzi Yalniz, Tonia Nesheiwat, Suzy Van Sanden, Joris Diels, Satish Valluri, Saad Z. Usmani, Jesus G. Berdeja, Sundar Jagannath, Tom Martin
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:690-701
This study estimated the comparative efficacy of ciltacabtagene autoleucel (cilta-cel; CARTITUDE-1), a chimeric antigen receptor (CAR)-T-cell therapy, versus 3 non-CAR-T therapies (belantamab mafodotin [DREAMM-2], selinexor plus dexamethasone [STORM
Autor:
Sarah A. Holstein, Fotis Asimakopoulos, Abdel Kareem Azab, Giada Bianchi, Manisha Bhutani, Leslie A. Crews, Tom Cupedo, Hannah Giles, Sarah Gooding, Jens Hillengass, Lukas John, Shari Kaiser, Lydia Lee, Kylee Maclachlan, Marcelo C. Pasquini, Flavia Pichiorri, Nina Shah, Monica Shokeen, Brian R. Shy, Eric L. Smith, Raluca Verona, Saad Z. Usmani, Philip L. McCarthy
Publikováno v:
Transplantation and Cellular Therapy, 28(8), 446-454. Elsevier Inc.
The Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Myeloma Intergroup conducted a workshop on Immune and Cellular Therapy in Multiple Myeloma on January 7, 2022. This workshop included presentations by basic, translational, and clinica
Autor:
Saad Z. Usmani, Hang Quach, Maria-Victoria Mateos, Ola Landgren, Xavier Leleu, David S. Siegel, Katja C. Weisel, Xiaomei Shu, Chuang Li, Meletios A. Dimopoulos
Publikováno v:
Blood Advances.
CANDOR (NCT03158688) is a phase 3, randomized, open-label trial comparing carfilzomib, daratumumab, and dexamethasone (KdD) versus carfilzomib and dexamethasone (Kd) in adults with relapsed/refectory multiple myeloma (RRMM) with 1-3 prior therapies.
Autor:
Manisha Bhutani, David M. Foureau, Myra Robinson, Fei Guo, Kateryna Fesenkova, Shebli Atrash, Barry Paul, Cindy Varga, Reed Friend, Mauricio Pineda-Roman, Katherine Rigby, James T. Symanowski, Sarah Norek, Mallory R. Tucker, Lawrence J. Druhan, Peter M. Voorhees, Saad Z. Usmani
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia.
Autor:
Ola Landgren, Katja Weisel, Laura Rosinol, Cyrille Touzeau, Mehmet Turgut, Roman Hajek, Peter Mollee, Jin Seok Kim, Natalie Shu, Xuguang Hu, Chuang Li, Saad Z. Usmani
Publikováno v:
British Journal of Haematology. 198:988-993
CANDOR compared the safety/efficacy of carfilzomib with dexamethasone and daratumumab (KdD) to carfilzomib with dexamethasone (Kd) in adults with relapsed/refractory multiple myeloma (RRMM). This CANDOR subgroup analysis evaluated outcomes based on c